Navigation Links
Brain tumors: New therapy surprisingly successful
Date:3/6/2009

This release is available in German.

The combination of two drugs produces a critical improvement in the treatment of certain brain tumours. This has been demonstrated by researchers at Bonn University working in co-operation with German and Swiss colleagues in a current study. They treated 39 patients who had been diagnosed with a so-called gliablastoma. The patients survived on average 23 months; with the standard therapy the mean would have been 14.6 months. Glioblastomas are the most aggressive and the commonest brain tumours. Left untreated, they prove fatal within just a few weeks. The study has been published in the Journal of Clinical Oncology (doi: 10.1200/JCO.2008.19.2195).

Even today, glioblastomas are untreatable something which even the new combination therapy cannot change. Nevertheless, Professor Dr. Ulrich Herrlinger of Bonn Universitys Schwerpunkt Klinische Neuroonkologie speaks of an outstanding success: "This unusually manifest extension of the survival time has surprised even us. Our results offer the opportunity to improve our grip on this aggressive form of cancer. Now, further investigations involving a larger number of patients are needed to optimise this therapy. Planning for this is already in hand in Bonn".

Up to now, doctors have treated glioblastomas using radiotherapy with concomitant chemotherapy. The "gold standard" for this for the last few years has been the active agent temozolomide. This is still celebrated as the most important breakthrough in the treatment of glioblastomas. The researchers combined this preparation with the drug lomustine. At the same time, the patients were given radiotherapy. The 39 patients thus treated survived the tumour for an average of 23.1 months. With the standard therapy, this time is over one third shorter. Seven patients even survived for over four years.

Genes decide the Success of the Therapy

It would appear that certain changes in the genotype are critical for the success of this therapy. "With eleven participants in the study, the information of one gene had been subjected to a characteristic modification", Ulrich Herrlinger declares. "These patients survived on average a good 34 months. With the other patients, these drugs appeared to bring no apparent advantage vis--vis pure radiotherapy at least, not in the dosage we tested. It is possible that a simple gene test could decide for whom a concomitant chemotherapy might be of benefit". One disadvantage of the new method are the side-effects. However, these mostly occur during the several months of the treatment phase. "After that they normally disappear completely, and the patients have no further complaints about them", Herrlinger stresses.

Working in co-operation with the Life&Brain-Zentrum in Bonn, the search is now on for more compatible, more effective, drugs. "Amongst other things, we now want to use cell cultures from original tumours to study precisely what the preparations we used in the study really effect", Dr. Martin Glas, one of the authors of the study, declares.


'/>"/>

Contact: Dr. Ulrich Herrlinger
Ulrich.Herrlinger@ukb.uni-bonn.de
49-228-287-19887
University of Bonn
Source:Eurekalert

Related medicine news :

1. Brain Tumor Drug May Help Spur Cancers Return
2. Brain tumor treatment may increase number of cancer stem-like cells
3. European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
4. Now Hear This: Brain Fitness Exercises Improve Listening
5. Nearly 1.4 Million Sustain Traumatic Brain Injuries Each Year
6. National Council on Disability Says More Needs to be Done for Service Members and Veterans With Post Traumatic Stress Disorder and Traumatic Brain Injury
7. Brain Adapts to Age-Related Eye Disease
8. UCI scientists to study brain region linked to autism, schizophrenia
9. Schizophrenia linked to signaling problems in new brain study
10. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
11. Sex is in the brain, says new research from Stanford
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... serving San Francisco and environs, is proud to announce an upgrade to the ... on the upgraded Yelp page on topics as diverse as Platelet Rich Plasma ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... ... February 26, 2017 , ... Functional imaging data supports improved ... study released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. ... effective in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao ...
(Date:2/24/2017)... ... 2017 , ... Only two months after the official release of The Private ... (France), XO Private has initiated a second print-run of its lavish luxury travel coffee ... across when open, weighs in at more than six kilos, retails at EUR 1,000 ...
(Date:2/24/2017)... ... ... In the Health Care IT campaign, Robert Herjavec discusses health IT security ... will be attacked, but when.” However, he and many others involved highlight a promising ... in auditing and monitoring have taken security in health care a very long way. ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  Interpace Diagnostics Group, ... provides clinically useful molecular diagnostic tests and pathology services, ... presented at the upcoming United States ... held March 4-10, 2017 in San Antonio, ... a review of data from the Company,s extensive experience ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
Breaking Medicine Technology: